[{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IN10018","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Ennovation Ventures"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BI 853520","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IN10018","moa":"Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BI 853520","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"Cobimetinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"InxMed \/ Hyfinity Investments","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Hyfinity Investments"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IN10018","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ InxMed","highestDevelopmentStatusID":"2","companyTruncated":"InxMed \/ InxMed"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OMTX705","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"InxMed","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ InxMed","highestDevelopmentStatusID":"3","companyTruncated":"InxMed \/ InxMed"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ifebemtinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by InxMed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.

                          Brand Name : IN10018

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 30, 2024

                          Lead Product(s) : Ifebemtinib,Garsorasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The license agreement provides InxMed with right to use EZWi-Fit® platform for the development of the next generation tumor-associated antigens targeting ADCs. InxMed will have the right for development, manufacturing, and commercialization of these ADC...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 19, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Escugen

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein alpha, which is investigated for the treatment of hard-to-treat solid tumors.

                          Brand Name : OMTX705

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 29, 2023

                          Lead Product(s) : OMTX705

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 17, 2023

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : GeneQuantum Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.

                          Brand Name : BI 853520

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 27, 2022

                          Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and Chi...

                          Brand Name : BI 853520

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 09, 2022

                          Lead Product(s) : Ifebemtinib,Cobimetinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Hyfinity Investments

                          Deal Size : $15.0 million

                          Deal Type : Series B Financing

                          blank

                          07

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Early clinical data on IN10018,a highly-selective adenosine triphosphate competitive FAK inhibitor showed its safety and efficacy in multiple tumor types, and latest research results and preclinical data demonstrated that IN10018 can also be effective in...

                          Brand Name : IN10018

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 14, 2022

                          Lead Product(s) : BI 853520,PEG-Liposomal Doxorubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : IN10018, formerly known as BI853520, is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor under clinical development stage in United States, Australia, and China.

                          Brand Name : IN10018

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2021

                          Lead Product(s) : BI 853520

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types.

                          Brand Name : BI 853520

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2021

                          Lead Product(s) : Ifebemtinib,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.

                          Brand Name : BI 853520

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 03, 2020

                          Lead Product(s) : Ifebemtinib,Cobimetinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Ennovation Ventures

                          Deal Size : $19.0 million

                          Deal Type : Series A Financing

                          blank